BBV 131
Alternative Names: BBV-131; HILLCHOLLatest Information Update: 02 Sep 2024
At a glance
- Originator MSD Wellcome Trust Hilleman Laboratories
- Developer Bharat Biotech; MSD Wellcome Trust Hilleman Laboratories
- Class Cholera vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Cholera
Most Recent Events
- 27 Aug 2024 Launched for Cholera (In adolescents, In children, In the elderly, In infants, Prevention, In adults) in India (PO) prior to August 2024
- 27 Aug 2024 Preregistration for Cholera (In adolescents, In children, In the elderly, In infants, Prevention, In adults) in India (PO) prior to August 2024
- 27 Aug 2024 Registered for Cholera (In adolescents, In children, In the elderly, In infants, Prevention, In adults) in India (PO) prior to August 2024